ArticleGenetics and molecular biology2026
Tissue Factor-inhibited Beclin1-autophagy via BCL2 overexpression suppresses the differentiation of human monocytes into mature osteoclasts.
Article in Genetics and molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tissue Factor (TF) can inhibit osteoclastogenesis. Moderate autophagy is an essential factor for osteoclastogenesis. As a molecule present in human monocytes, TF can inhibit autophagic activity through B-cell lymphoma-2 (BCL2) overexpression; this suggests that the anti-osteoclastogenic role of TF may occur in human monocytes and be associated with BCL2-dependent autophagy. Our study aimed to explore the relationship between TF-regulated BCL2-autophagy signaling and osteoclast-differentiation fate of human monocytes. Cell enrichment based on fluorescence-activated cell sorting (FACS) was used to enrich TF-associated monocytic clusters. Then, a series of functional assays were performed to investigate the roles of TF in monocytic parameters associated with osteoclast precursors (OCPs). The results showed that under osteoclastic induction, the osteoclastogenic ability and autophagic activity in enriched TF- monocytes were enhanced whereas TF+ monocytes exhibited opposite results. BCL2 expression and the interaction between BCL2-Beclin1 in TF- monocytes decreased while those of TF+ monocytes were contrary. The osteoclastogenic ability of TF- monocytes decreased again with autophagy inhibition with Beclin1 underexpression. The osteoclastogenic ability of TF+ monocytes increased again with enhanced autophagy with BCL2 inhibition and Beclin1 overexpression. Overall, TF increases BCL2-Beclin1 stability by upregulating BCL2 expression, thereby decreasing Beclin1-dependent autophagy and subsequent monocytic osteoclastogenesis in human monocytes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.